Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis
Persistence with dupilumab treatment remained high at 12 months, with more than 40.0% of patients who discontinued dupilumab treatment reinitiating it within 12 months in this real-world practice setting.
Authors
- A. Gandhi (ORCID: https://orcid.org/0000-0001-8372-663X)
- Scott D. Nash (ORCID: https://orcid.org/0000-0001-5741-8537)
- Jayant M. Pinto (ORCID: https://orcid.org/0000-0003-2838-490X)
- Mark Corbett (ORCID: https://orcid.org/0000-0001-9298-3072)
- Bruno Martins (ORCID: https://orcid.org/0000-0001-7484-1011)
- Mirko Fillbrunn (ORCID: https://orcid.org/0000-0002-8037-703X)
- Zhixiao Wang (ORCID: https://orcid.org/0000-0003-1928-3103)
- Chao Chen (ORCID: https://orcid.org/0000-0003-2569-5083)
- Min Yang (ORCID: https://orcid.org/0000-0002-4864-6658)
Institutions
- Regeneron (United States) (US)
- Sanofi (France) (FR)
- University of Chicago (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.jacig.2025.100557
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals